drugset / Trial / NCT05328297
A Study of JNJ-55308942 in the Treatment of Bipolar Depression
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (BD) in a major depressive episode (MDE) at Week 6.
Timeline
- Start
- 2022-06-03
- Primary completion
- 2024-05-17
- Completion
- 2024-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZANVIPIXANT | Small molecule | — | Oral |